Ecto-5′-nucleotidase and thiopurine cellular circulation: Association with cytotoxicity

Drug Metabolism and Disposition

Volumn 38, Issue 12, 2010, Pages 2329-2338

  Li, Fang ^a   Fridley, Brooke L ^b   Matimba, Alice ^a   Kalari, Krishna R ^b   Pelleymounter, Linda ^a   Moon, Irene ^a   Ji, Yuan ^a   Jenkins, Gregory D ^b   Batzler, Anthony ^b   Wang, Liewei ^a   Weinshilboum, Richard M ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ECTO 5' NUCLEOTIDASE; MERCAPTOPURINE; MULTIDRUG RESISTANCE PROTEIN 4; NUCLEOSIDE TRANSPORTER; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; 5' NUCLEOTIDASE; ABCC4 PROTEIN, HUMAN; METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; CELL PROLIFERATION; CIRCULATION; CONTROLLED STUDY; CYTOTOXICITY; DNA FLANKING REGION; ETHNIC GROUP; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYDROLYSIS; IC 50; LYMPHOBLASTOID CELL LINE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSIENT TRANSFECTION; CELL LINE; GENETICS; METABOLISM;

5'-NUCLEOTIDASE; 6-MERCAPTOPURINE; CELL LINE; HUMANS; METHYLTRANSFERASES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; THIOGUANINE;

EID: 78649580562     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.035220     Document Type: Article

References (41)

1. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, and Young JD (2004) The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 447:735-743.
2. Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF, and Relling MV (2001) Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 61:5810-5816.
3. Dervieux T and Boulieu R (1998a) Identification of 6-methylmercaptopurine derivative formed during acid hydrolysis of thiopurine nucleotides in erythrocytes, using liquid chromatographymass spectrometry, infrared spectroscopy, and nuclear magnetic resonance assay. Clin Chem 44:2511-2515.
4. Dervieux T and Boulieu R (1998b) Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 44:551-555.
5. Erdmann GR, France LA, Bostrom BC, and Canafax DM (1990) A reversed phase high performance liquid chromatography approach in determining total red blood cell concentrations of 6-thioguanine, 6-mercaptopurine, methylthioguanine, and methylmercaptopurine in a patient receiving thiopurine therapy. Biomed Chromatogr 4:47-51.
6. Erdmann GR, Steury JC, Carleton BC, Stafford RJ, Bostrom BC, and Canafax DM (1991) Reversed-phase high-performance liquid chromatographic approach to determine total lymphocyte concentrations of 6-thioguanine, methylmercaptopurine and methylthioguanine in humans. J Chromatogr 571:149-156.
7. Fotoohi AK, Lindqvist M, Peterson C, and Albertioni F (2006) Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem Biophys Res Commun 343:208-215.
8. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA, Roberts RL, and Kennedy MA (2003) Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 18:395-400.
9. Gray JH, Owen RP, and Giacomini KM (2004) The concentrative nucleoside transporter family, SLC28. Pflugers Arch 447:728-734.
10. Hill DL and Bennett LL Jr (1969) Purification and properties of 5-phosphoribosyl pyrophosphate amidotransferase from adenocarcinoma 755 cells. Biochemistry 8:122-130.
11. Honchel R, Aksoy IA, Szumlanski C, Wood TC, Otterness DM, Wieben ED, and Weinshilboum RM (1993) Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA. Mol Pharmacol 43:878-887.
12. Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, et al. (2007) A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci USA 104:9758-9763.
13. Huang RS, Duan S, Kistner EO, Bleibel WK, Delaney SM, Fackenthal DL, Das S, and Dolan ME (2008) Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res 68:3161-3168.
14. Jakobs ES, Van Os-Corby DJ, and Paterson AR (1990) Expression of sodium-linked nucleoside transport activity in monolayer cultures of IEC-6 intestinal epithelial cells. J Biol Chem 265:22210-22216.
15. Krishnamurthy P, Schwab M, Takenaka K, Nachagari D, Morgan J, Leslie M, Du W, Boyd K, Cheok M, Nakauchi H, et al. (2008) Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res 68:4983-4989.
16. Lennard L (1987) Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatogr 423:169-178.
17. Lennard L (1992) The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 43:329-339.
18. Lennard L, Rees CA, Lilleyman JS, and Maddocks JL (1983) Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 16:359-363.
19. Lennard L and Singleton HJ (1992) High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 583:83-90.
20. Lennard L, Van Loon JA, Lilleyman JS, and Weinshilboum RM (1987) Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 41:18-25.
21. Li L and Abecasis GR (2006) Mach 1.0: rapid haplotype reconstruction and missing genotype inference. Am J Hum Genet S79:2290.
22. Li L, Fridley B, Kalari K, Jenkins G, Batzler A, Safgren S, Hildebrandt M, Ames M, Schaid D, and Wang L (2008) Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res 68:7050-7058.
23. Mawatari H, Kato Y, Nishimura S, Sakura N, and Ueda K (1998) Reversed-phase high-performance liquid chromatographic assay method for quantitating 6-mercaptopurine and its methylated and non-methylated metabolites in a single sample. J Chromatogr B Biomed Sci Appl 716:392-396. (Pubitemid 28464589)
24. Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z, and Wang L (2009) FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 16:259-266.
25. Peng XX, Shi Z, Damaraju VL, Huang XC, Kruh GD, Wu HC, Zhou Y, Tiwari A, Fu L, Cass CE, et al. (2008) Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leuk Res 32:799-809.
26. Pieters R, Huismans DR, and Veerman AJ (1987) Are children with lymphoblastic leukaemia resistant to 6-mercaptopurine because of 5′-nucleotidase? Lancet 2:1471.
27. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, and Fridland A (1999) MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5:1048-1051.
28. Storey J (2003) The positive false discovery rate: a Bayesian interpretation and the q-value. Ann Stat 31:2013-2035.
29. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, Spurr N, Lennard L, Wieben E, and Weinshilboum R (1996) Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 15:17-30.
30. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, and Evans WE (1996) Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 58:694-702.
31. Tay BS, Lilley RM, Murray AW, and Atkinson MR (1969) Inhibition of phosphoribosyl pyrophosphate amidotransferase from Ehrlich ascites-tumour cells by thiopurine nucleotides. Biochem Pharmacol 18:936-938.
32. Wang L, Nguyen TV, McLaughlin RW, Sikkink LA, Ramirez-Alvarado M, and Weinshilboum RM (2005) Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc Natl Acad Sci USA 102:9394-9399.
33. Wang L, Sullivan W, Toft D, and Weinshilboum R (2003) Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics 13:555-564.
34. Wang L and Weinshilboum R (2006) Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 25:1629-1638.
35. Ward JL, Sherali A, Mo ZP, and Tse CM (2000) Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. Ent2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. J Biol Chem 275:8375-8381.
36. Weinshilboum RM and Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651-662.
37. Weinshilboum RM and Wang L (2006) Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Hum Genet 7:223-245.
38. Wielinga PR, Reid G, Challa EE, van der Heijden I, van Deemter L, de Haas M, Mol C, Kuil AJ, Groeneveld E, Schuetz JD, et al. (2002) Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol 62:1321-1331.
39. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, and Spencer F (2004) A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 99:909-917.
40. Zaza G, Cheok M, Yang W, Panetta JC, Pui CH, Relling MV, and Evans WE (2005) Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 106:1778-1785.
41. Zimmermann H (1992) 5′-Nucleotidase: molecular structure and functional aspects. Biochem J 285 (Pt 2):345-365.